A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
N/A
1969-12-31
The purpose of this study is to look at the effects of different methods of birth control
(oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV).
This study will also evaluate the differences in men and women in how the body absorbs, makes
available, and removes ZDV.
Past research has shown that the effectiveness of ZDV as an anti-HIV drug might be decreased
in individuals who use certain methods of birth control. ZDV may also have different effects
in men compared to women.
Medical Treatment of Endometriosis-Associated Pelvic Pain
Completed
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 3
2004-07-01
The Specific Aim of this project is to compare the efficacy and cost-effectiveness of
continuous oral contraceptives versus leuprolide/norethindrone in the treatment of
endometriosis-associated chronic pelvic pain. This comparison will be based on a randomized,
double-blind, trial of women with chronic pelvic pain who have been diagnosed with
endometriosis at the time of surgery within the last 3 years. We hypothesize that, over a
12-month period of postoperative treatment, the efficacy of oral contraceptives is no worse
than leuprolide/norethindrone, and that treatment with oral contraceptives is more
cost-effective.
Study of Bleeding With Extended Administration of an Oral Contraceptive
Completed
Warner Chilcott
Phase 2
2006-06-01
This is an non-comparative study. There is no statistical hypothesis. The effects of
extension of treatment on bleeding will be recorded and described.
Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial
Completed
Kaiser Permanente
N/A
2003-04-01
To determine the relative efficacy of multidose medroxyprogesterone acetate (MPA, Provera)
and a multidose, monophasic combination oral contraceptive in the treatment of
hemodynamically stable women with non-gestational, acute uterine bleeding.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
